A bifunctional-biased mu-opioid agonist–neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects
Authors:
- 26 April 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 159 (9) , 1705-1718
Abstract
Opioid analgesics, such as morphine, oxycodone, and fentanyl, are the cornerstones for treating moderate to severe pain. However, on chronic administration, their efficiency is limited by prominent side effects such as analgesic tolerance and dependence liability. Neuropeptide FF (NPFF) and its receptors (NPFF1R and NPFF2R) are recognized as an important pronociceptive system involved in opioid-induced hyperalgesia and analgesic tolerance. In this article, we report the design of multitarget peptidomimetic compounds that show high-affinity binding to the mu-opioid receptor (MOPr) and NPFFRs. In vitro characterization of these compounds led to identification of KGFF03 and KGFF09 as G-protein–biased MOPr agonists with full agonist or antagonist activity at NPFFRs, respectively. In agreement with their biased MOPr agonism, KGFF03/09 showed reduced respiratory depression in mice, as compared to the unbiased parent opioid agonist KGOP01. Chronic subcutaneous administration of KGOP01 and KGFF03 in mice rapidly induced hyperalgesia and analgesic tolerance, effects that were not observed on chronic treatment with KGFF09. This favorable profile was further confirmed in a model of persistent inflammatory pain. In addition, we showed that KGFF09 induced less physical dependence compared with KGOP01 and KGFF03. Altogether, our data establish that combining, within a single molecule, the G-protein–biased MOPr agonism and NPFFR antagonism have beneficial effects on both acute and chronic side effects of conventional opioid analgesics. This strategy can lead to the development of novel and potent antinociceptive drugs with limited side effects on acute and chronic administration.Keywords
This publication has 53 references indexed in Scilit:
- A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with MorphineThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Opioid receptors: distinct roles in mood disordersTrends in Neurosciences, 2013
- Variation of the Net Charge, Lipophilicity, and Side Chain Flexibility in Dmt1-DALDA: Effect on Opioid Activity and BiodistributionJournal of Medicinal Chemistry, 2012
- Delta opioid receptor analgesiaBehavioural Pharmacology, 2011
- Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatmentsBritish Journal of Pharmacology, 2011
- Ligand-Directed Trafficking of the δ-Opioid ReceptorIn Vivo: Two Paths Toward Analgesic ToleranceThe Journal of Neuroscience, 2010
- In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel μ opioid analgesic with reduced propensity to alter motor functionEuropean Journal of Pharmaceutical Sciences, 2010
- In Vivo Delta Opioid Receptor Internalization Controls Behavioral Effects of AgonistsPLOS ONE, 2009
- De Facto Long-term Opioid Therapy for Noncancer PainThe Clinical Journal of Pain, 2008
- Critical issues on opioids in chronic non-cancer pain:Pain, 2006